Collaboration aimed at subcutaneous biologics development and commercialization
- Alteogen and Biogen have formed a strategic partnership.
- The agreement focuses on Hybrozyme technology for biologics.
- This collaboration aims to enhance drug delivery methods.
Alteogen has entered a licensing agreement with Biogen to advance the development and commercialization of Hybrozyme-based biologics. This arrangement is part of a strategic collaboration to innovate subcutaneous drug delivery methods. The Hybrozyme technology aims to enhance the pharmacokinetics of biologics, potentially making treatments more effective.
The agreement will leverage both companies' expertise, with Biogen expected to play a significant role in the commercialization process. Hybrozyme technology enables the creation of biologics that can be administered via subcutaneous injections rather than intravenous delivery. This could improve patient convenience and adherence to treatment regimens.
As both companies work towards this goal, the partnership underscores the growing emphasis on advanced drug delivery systems in the biotechnology field. The collaboration is anticipated to accelerate the clinical development of these novel therapeutics, which could have a significant impact on patient care.
